A

Amgen

Makes biotech medicines for serious illnesses

Global Markets & Policy Finance Director

Full-TimeUpdated on 10/21/2026
No salary listed
Expert
Master's
Hyderabad, Telangana, India
In Person
Finance & BankingCorporate Finance & FP&A

About the job

Requirements
  • A Chartered Accountant, Cost Accountant, Certified Public Accountant, or a Master's degree in Economics, Finance, or Business Administration is required.
  • At least 18 years of progressive experience in financial planning and analysis or a related finance discipline is required.
  • Commercial Finance and/or Financial Planning & Analysis experience, including revenue and operating expense planning, is required.
  • Demonstrated experience building, scaling, or transforming Finance teams and capabilities, ideally within a global organization, is required.
  • Experience working across multiple markets, regions, business units, or global functions in a matrixed environment is required.
  • Strong understanding of forecasting, budgeting, long-range planning, financial reporting, and performance management is required.
  • Demonstrated ability to standardize and simplify Finance processes while maintaining strong business partnership is required.
  • Strong leadership and talent-development capabilities, including experience leading and developing high-performing Finance teams, are required.
  • Strong communication and influencing skills, including the ability to partner effectively with senior Finance and business leaders globally, are required.
  • Strategic and proactive thinking, a succinct point of view and business perspective, and the ability to translate financial analysis into actionable recommendations are required.
  • Experience leveraging technology, automation, analytics, and artificial intelligence to improve Finance processes and decision support is required.
  • The ability to prioritize effectively and adapt quickly to changing business requirements is required.
Responsibilities
  • Lead revenue and operating expense planning and forecasting activities in partnership with Global, Regional, and Local Finance teams, supporting short-term forecasts, annual budgets, and long-range planning.
  • Establish standardized, scalable planning and analytical processes across commercial organizations while accommodating differences across products, markets, and regions.
  • Deliver financial analysis and business insights related to revenue performance, commercial investments, operating expenses, productivity, and resource allocation.
  • Partner with Finance and Commercial leadership to identify opportunities to improve financial performance, optimize investments, and increase productivity.
  • Build capabilities using automation, advanced analytics, artificial intelligence, and standardized data to improve forecast quality, reduce manual work, and accelerate financial insights and decision-making.
  • Establish governance, controls, service expectations, and accountability across activities performed by the Amgen India team and its Finance partners globally.
  • Support financial close, management reporting, variance analysis, forecasting, and other recurring Finance processes, maintaining accuracy, consistency, timeliness, and compliance.
  • Lead cross-functional and cross-Finance initiatives to simplify and improve Finance processes, reduce duplication, and increase consistency across Global Markets & Policy.
  • Recruit, retain, develop, and coach Finance talent, creating opportunities for team members to build commercial and financial expertise and take on increasingly complex responsibilities.
  • Provide senior leadership with a concise business and financial perspective, translating complex financial information into insights and recommendations.
  • Lead the Amgen India organization and influence across a matrixed global organization.
  • Develop the Global Markets & Policy Commercial Finance team, initially comprising approximately seven Finance professionals, and expand the organization's scope and capabilities over time.
Desired Qualifications
  • Experience building, scaling, or transforming Finance teams and capabilities within a global organization is preferred.

About the company

Amgen develops and makes biologic medicines, which are drugs built from proteins and antibodies grown in living cells, for serious conditions such as heart disease, cancer, and bone loss. Its anemia drug Epogen, approved in 1989, became one of the biotechnology industry's first blockbuster medicines. Amgen grows these drugs in large tanks called bioreactors, and its products include the cholesterol drug Repatha, the bone-building drug Evenity, and the severe asthma drug Tezspire. It earns money by selling these medicines, mostly through large drug wholesalers that supply hospitals and pharmacies. Amgen was founded in 1980 and is based in Thousand Oaks, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Get referred to Amgen

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Growth is broad-based: 22 products grew at least 10%, lifting June 2026 quarter revenue 10% to $10.1 billion.
  • Stock grants gained value: Amgen shares rose 27% from January to October 9, 2026, versus 10% for rival Eli Lilly.
  • Many U.S. roles are remote: 145 of Amgen's 615 U.S. job openings in October 2026 were fully remote.

What critics are saying

  • Its 2025 best seller is shrinking: cheaper copies cut bone drug Prolia's sales 32% in the June 2026 quarter.
  • MariTide, Amgen's obesity bet, faces a giant: Lilly's Mounjaro and Zepbound outsold all of Amgen in the June 2026 quarter.
  • Most tech openings are in India: 156 of Amgen's 210 information systems jobs in October 2026 were in Hyderabad.

What makes Amgen unique

  • It copies rivals' blockbusters too: Pavblu, its version of Regeneron's eye drug Eylea, sold $700 million in 2025.
  • Amgen hunts drug targets in a nation's DNA: its Icelandic unit deCODE has genetic data on two-thirds of Iceland's adults.
  • Amgen opened a U.S. cancer-drug class: Blincyto, approved in 2014, was the first to tether immune cells to cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Professional Development Budget
  • Conference Attendance Budget

Company News

Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Amgen raises 2026 revenue forecast to $38.8B as shares gain 15.2%

Amgen raised its fiscal 2026 revenue forecast on August 4 to $38.8 billion at the midpoint, up 2.6% from $37.8 billion. Adjusted earnings per share guidance rose to $22.90 from $22.40. Six key growth drugs grew 26% from a year earlier and made up nearly 70% of product sales in the June quarter. Repatha sales rose 37% to $953 million, offsetting a 33% drop in Prolia and XGEVA sales as biosimilar copies launched. Total revenue rose 10%. The stock has gained 15.2% since the release, against 1.9% for the S&P 500. It closed at $434.03 on October 15, above both its 50-day and 200-day averages. Reaching the midpoint requires $20.1 billion in the second half. Amgen's next report is expected around November 3.

Yahoo Finance
Oct 8th, 2026
Amgen invests $2.6B in manufacturing for MariTide obesity drug ahead of Phase III results

Amgen is testing MariTide, an experimental obesity drug designed to be dosed monthly or less frequently. The therapy has advanced into late-stage Phase III trials, with nine studies currently running and three more planned. Executives reported strong enrolment during the company's second-quarter 2026 earnings call on 4 August 2026. Amgen expects capital spending of about $2.6 billion in 2026, partly to scale manufacturing capacity for MariTide's eventual launch. The company is investing across its US manufacturing sites in North Carolina, Ohio, and Puerto Rico. Amgen stock has returned 44% over the past twelve months, outpacing the S&P 500's 17.1% gain. The company reported $38.1 billion in revenue over the last twelve months, up from $34.9 billion a year earlier.

Yahoo Finance
Sep 29th, 2026
Amgen lifts dividend 6%, but eroding Prolia and Enbrel sales shift focus to MariTide Phase 3

Amgen raised its quarterly dividend 6% to $2.52 per share, marking its 14th consecutive annual increase since starting payouts in 2011. The biotech now pays $10.08 annually, yielding 2.36% at current share prices of $418.13. The dividend appears well covered. Amgen generated $8.1 billion in free cash flow in 2025 against $5.1 billion in dividend payments. Second quarter 2026 free cash flow reached $3.5 billion whilst dividends consumed $1.4 billion. However, biosimilar competition is eroding legacy revenue. Prolia and XGEVA sales dropped 33% whilst Enbrel fell 37%. The company carries $57 billion in debt. Future dividend growth may hinge on Phase 3 results for MariTide, Amgen's obesity candidate. The company follows a steady raise pattern similar to Johnson & Johnson, contrasting with Pfizer's post-COVID payout struggles.

Yahoo Finance
Sep 26th, 2026
Vertex and Amgen deliver promising pipeline updates as both outperform market

Vertex Pharmaceuticals reported strong second-quarter results, with revenue rising 12% year-over-year to $3.33 billion and earnings per share climbing 8% to $4.31. The company posted positive Phase 2b results for inaxaplin, an experimental treatment for APOL1-mediated kidney disease, showing it reduced proteinuria in patients with modest protein levels and those with type 2 diabetes. Vertex expects approval for povetacicept, a treatment for IgA nephropathy, by November. The company continues diversifying beyond its core cystic fibrosis franchise, which provides predictable revenue as patients require lifelong treatment. Meanwhile, Amgen has also outperformed the broader market this year, though specific recent developments were not detailed in the source material.